Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Inclusion Criteria: * CASE TISSUE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * CASE BLOODS AND URINE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * HEALTHY CONTROL BLOODS AND URINE: * Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy * Age \>= 18 years Exclusion Criteria: * CASE TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * The current target pathology is a recurrence * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * RENAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillar…